Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

• Published in: Vaccines (Basel) Vol. 10; no. 8; p. 1217
• Main Authors: Parés-Badell, Oleguer, Zules-Oña, Ricardo, Armadans, Lluís, Pinós, Laia, Borrás-Bermejo, Blanca, Otero, Susana, Rodrigo-Pendás, José Ángel, Vivet-Escalé, Martí, Cossio-Gil, Yolima, Agustí, Antònia, Aguilera, Cristina, Campins, Magda, Martínez-Gómez, Xavier
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29-07-2022; MDPI
• Subjects: adverse reactions; booster dose; Chronic illnesses; Confidence intervals; Coronaviruses; COVID-19; COVID-19 vaccines; COVID-19-vaccination; Cross-sectional studies; Gender; Health care; Health care reform; health care workers; Homology; Hospitals; Infections; Medical personnel; Medical research; Medicine, Experimental; Messenger RNA; mRNA; mRNA vaccines; Questionnaires; SARS-CoV-2; Self report; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Surveys; Vaccination; Vaccines; Workers; Spain
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10081217

The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.